Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis

NCT03561701 is registered in ClinicalTrials.gov with Mycovia Pharmaceuticals Inc. as lead sponsor.

NCT NCT03561701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03561701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules in the Treatment of Subjects With Recurrent Vulvovaginal Candidiasis
Lead sponsor
Mycovia Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 23, 2018
Completion date
August 3, 2021
Enrollment
425 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent vulvovaginal candidiasis